Milestone Pharmaceuticals Posts First Product Revenue as CARDAMYST Launch Costs Drive Wider Losses
MIST is trading near its 52-week low of $1 (10% above the low).
Summary
Milestone Pharmaceuticals recorded its first product revenue from CARDAMYST, but launch costs drove losses higher. The cash runway remains solid, and the CEO's termination of a large planned stock sale eliminates a potential overhang.
Key Events · Earnings and Guidance · MIST
-
First CARDAMYST Revenue
Product revenue reached $0.6M in Q2 2026 and $0.8M for H1 2026, marking the first sales since the February 2026 launch.
-
Commercialization Costs Surge
Selling, general and administrative expenses jumped to $22.6M in Q2 2026 from $8.9M a year earlier, driven by the CARDAMYST launch.
-
Net Loss Widens
Net loss reached $28.6M in Q2 2026, up from $13.0M in Q2 2025, as operating expenses outpaced early revenue.
-
Strong Cash Position
Cash and equivalents stood at $169.7M as of June 30, 2026, bolstered by the $75M royalty financing closed in January 2026.
Analysis · MIST · Life Sciences
The first full quarter of CARDAMYST sales brought in $0.6M in revenue, but commercialization expenses pushed SG&A to $22.6M—more than double the prior-year period. As a result, the quarterly net loss widened to $28.6M. Cash remains robust at $169.7M following the $75M royalty deal, though the burn rate is accelerating. In a move that removes a near-term overhang, the CEO terminated a 10b5-1 plan after selling only 80,000 of a planned 2.1M shares. A new ATM program was established but has not yet been tapped. Meanwhile, the Phase 3 AFib-RVR trial is underway, with first patient enrollment expected in H2 2026.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29% of the 1483 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIST was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.1M. The 52-week trading range was $1.00 to $3.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.